Although the causes of cancer lie in mutations or epigenetic changes at the genetic level, their molecular manifestation is the dysfunction of biochemical pathways at the protein level. Therefore, only by studying the proteome can we gain functional understanding of the pathways that are deranged in cancer. Rather than just identifying proteins, functional proteomics focuses on the generation of information about proteins, such as expression levels, post-translational modifications (PTMs) and activity, which directly contribute to a functional understanding of a biological system. Functional proteomics feeds directly into the systematic analysis of biochemical networks, often using mathematical modelling or other systems biology tools. It also provides readouts for chemical biology and chemical genetics that are necessary to interpret the action of drugs.
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, fluorescence-and flow cytometry-based detection of proteins and PTMs 2 , and optical spectroscopic methods of proteome analysis 3, 4 . These latter techniques are promoted by an everincreasing repertoire of specific antibodies against proteins and PTMs, and bring single-cell proteomics into reach.
Proteomics has been widely applied to cancer research and the mapping of cancerous signalling pathways and the vast literature exceeds the scope of a single Review. Therefore, we will use three main cancer pathways, epidermal growth factor receptor (EGFR, also known as ERBB1), breakpoint cluster region (BCR)-ABL1 and ERK, as examples to describe some of the new paradigms in cancer signalling that owe their discovery to proteomics. The EGFR network is frequently altered in various human cancers and has been extensively studied using proteomics both at the level of the receptor and the downstream pathways. BCR-ABL1 stands out among oncogenes, as chronic myelogenous leukaemia (CML) -which is caused by this fusion gene -is with few exceptions strictly dependent on BCR-ABL1 function 5 . Thus, BCR-ABL1 signalling could reveal the minimum assortment of pathways required for transforming a human cell. The ERK pathway is a crucial effector of the EGFR and BCR-ABL1 pathways. Hence, although other important pathways -such as the mTOR pathway -are not discussed here, our selection of signalling pathways allows us to describe general principles and representative new insights into cancer signalling pathways that we have gained through proteomics. As technological and methodological advances
Scaffold protein
A protein that can simultaneously bind two or more other proteins, and thereby facilitate physical and functional interactions between the client proteins that bind to it.
Matrix management
A flexible management approach that assigns people with the required skill sets to projects, typically drawing expertise from different departments. This comparison is used to illustrate that a protein with a defined molecular function, such as a kinase, can be used by several different pathways.
Modularization
The grouping of different functions into a single unit (module) so that the output of the module can be treated as a single functional entity, such as the ability of different combinations of components of protein complexes to achieve the same output.
Non-oncogene addiction
This occurs when the action of oncogenes needs to be supported by apparently normally functioning signalling pathways that allow the mutated oncogene to develop its transforming activity.
are integral to functional proteomics, we briefly discuss the experimental approaches, although the emphasis of this Review is on the biological findings.
We begin by discussing protein-protein interactions. Most cellular processes, including signal transduction, require the coordinated formation of multiprotein complexes. A main focus in functional proteomics has been to analyse the formation of specific protein-protein interactions and the consequent assembly of macro molecular protein complexes, particularly how these assemblies are regulated by scaffold proteins and PTMs and how they affect pathway function. We then discuss selected PTMs associated with cancer pathways. Although phosphorylation and glycosylation have dominated the posttranslational area of research, we increasingly realize that a large range of modifications, including ubiquitylation, play crucial functions in cellular regulation. We conclude with an outlook towards single-cell proteomics and the clinical relevance of functional cancer proteomics.
Protein-protein interactions
Protein-protein interactions have important roles in cellular processes. However, deconvoluting the complex nature of these interactions has proved to be difficult. Stable protein assemblies function as 'molecular machines' in all cellular processes, from transcription machineries in the nucleus, to ribosomes that translate mRNA into proteins and to molecular motors that generate the forces for intracellular transport and cell motility. These stable protein complexes are highly amenable to proteomic analysis and powerful isolation procedures have been developed to purify stable protein complexes for MS analysis. They usually use tandem affinity purification (TAP) tags, which allow the efficient purification of stable protein complexes by a sequential pulldown-elution-pulldown protocol 6 . Genome-wide interaction studies 7, 8 using this methodology showed that the yeast proteome is organized in 500-550 protein complexes, thus experimentally confirming the concept that organization based on protein-protein interactions can specify biological functions. Does this concept also apply to molecular information processors in mammalian cells?
In principle, dynamically changing protein interactions could provide the speed, plasticity and compartmentalization needed to process signals that encode temporal and spatial information. However, these associations may be transient and feature complex dynamics and stoichiometries between different complexes that compete for the same component. Thus, these interactions are often regulated through transient PTMs such as phosphorylation. Specific phosphorylation-dependent-binding motifs have been identified on many signalling proteins. For example, activated receptor tyrosine kinases (RTKs) phosphorylate tyrosines in their cytoplasmic kinase domains which provide binding sites for downstream effectors that direct the assembly of transient signalling complexes [9] [10] [11] . RTKs, especially those of the ErbB family, are often overexpressed or mutated in cancer, which results in the assembly of aberrant signalling complexes 9, 12 . The technical aspects of mapping protein interactions in signalling pathways have been covered in recent reviews [13] [14] [15] . The methodologies rely on the application of quantitative MS techniques 16 
and often require the generation of dynamic interaction maps 17, 18 . One of the main advantages is that the quantitative techniques can separate true interactors from contamination 19 . However, substantial challenges remain. Methodologies for measuring the specific occupancy of PTM sites on individual protein molecules are limited. Similarly, in the currently used proteomic pulldown experiments, we cannot distinguish between different subcomplexes, which is akin to having a corporate organization chart with all the names but no affiliations to departments. However, emerging evidence suggests that signal transduction uses a matrix management approach, in which one component fulfils different tasks in different complexes. Mapping this matrix is further complicated by the fact that the structure of a complex can change dynamically over time, and certain complexes may only be necessary for a limited time to activate their downstream biological pathways.
This provides a major challenge, as it may be failures in matrix management that drive cancer rather than individual mutations altering one function of a protein. The crosstalk between protein complexes also contributes to the robustness of cancer signalling by allowing modularization 20 and generating molecular heterogeneity 21 , which together allow rapid and versatile adaptation. This view is encapsulated in the concept of non-oncogene addiction, which highlights the importance of normal pathways in supporting the biological effects of mutated pathways 22 . This concept has wide ramifications for the design of rational cancer therapies and the identification of promising targets. The hope is that the common phenomenon of
At a glance
• Signalling pathways are commonly deranged in cancer and quantitative proteomics offers powerful approaches to map these pathways and their aberrations in cancer.
• Hubs in signalling pathways feature multiple protein interactions, which are involved in information processing and specification of the biological responses. These networks can be mapped by interaction proteomics to reveal molecular mechanisms of transformation and potential targets for therapeutic interventions.
• The oncogenic actions of the epidermal growth factor receptor (EGFR) network and the breakpoint cluster region (BCR)-ABL1 oncogene rely on the dynamic assembly of multiprotein complexes, which activate multiple downstream pathways that cooperate in transformation. In EGFR networks, the oncogenic potential increases with the number of downstream pathways being activated.
• The dynamic assembly of protein complexes is regulated by post-translational modifications (PTMs) such as phosphorylation. Advances in phosphoproteomics allow the targeted and global mapping of phosphorylation networks, confirming that kinase networks play major parts in cancer and offer numerous new targets for therapeutic intervention.
• In addition to phosphorylation, a role for PTMs in the regulation of cancer cell biology is becoming increasingly recognized. For example, proteomic studies of ubiquitylation are beginning to unravel extensive alterations that contribute to cancer, such as growth factor receptor activation, transcription factor function, protein localization and degradation.
• Dynamic changes in protein abundance and PTMs may also contribute to cancer cell heterogeneity, and new proteomics technologies based on optical, spectroscopic and microarray methods are being developed to analyse individual cells.
SH2 domain
This domain was first discovered as a conserved domain in the Src kinase family. It recognizes short peptide motifs that contain a phosphorylated tyrosine residue and thus function as phosphotyrosine-dependent protein interaction sites.
cancer drug resistance can be conquered by the parallel targeting of oncogenic pathways and non-oncogene addictive alterations.
Protein complexes. The EGFR pathway is one of the most extensively studied signalling pathways relevant to cancer 23 and the EGFR interactome is one of the most well-described interactomes, both biochemically 24 and theoretically 25, 26 (FIG. 1) . Major questions are how EGFR coordinates diverse biological responses and how response specificity is generated. Functional proteomics has deciphered the components of protein complexes formed by EGFR and has also contributed to an understanding of the topological organization of the downstream signalling pathways.
MS-based quantitative proteomics to analyse proteins that interact with phosphopeptides that are phosphorylated in response to ligand binding showed that the four members of the ErbB family have differential preferences for interaction partners 27 . Interestingly, growth factor receptor-bound protein 2 (GRB2), which initiates activation of the ERK pathway, and PI3K, which activates the AKT pathway, have several binding sites on one receptor. Multimeric binding could be a simple mechanism to transmit the strength of the input into these two pathways. A complementary approach used protein microarrays comprising most known SH2 domains and phosphotyrosine-binding (PTB) domains in the human genome to measure the dissociation constants of each domain for 61 peptides that are physiologically tyrosine phosphorylated when EGFR and ERBB2-4 are activated 28 . The resulting systematic interaction maps showed that the binding complement differs between receptor dimers, with ERBB2 (also known as HER2)-ERBB3 having the most interactions, followed by EGFR-ERBB3>EGFR-ERBB2>EGFR-EGFR. This distribution correlates with the transforming potencies of ErbB dimers 29, 30 , indicating that an increase in interaction partners enhances oncogenicity. Interestingly, EGFR and ERBB2 but not ERBB3 became increasingly promiscuous when their expression level or activation state was increased, resulting in the binding of more proteins and the activation of more signalling pathways at higher concentrations of these receptors 28 . This result may explain why these receptors are often overexpressed in cancer.
Comparison of the interactors identified in these two studies showed overlaps as well as differences; for example, signal transducer and activator of transcription 5 (STAT5) was found to bind only to EGFR and ERBB4 in the MS study. These differences could be due to different experimental systems or reflect differences in the technologies used in the two studies.
These studies also suggested that the biological specificity of receptor signalling is determined by the composition of the signalling complexes assembled by the receptor and the ligand-induced changes in its interactome. Implicit in this hypothesis is the assumption that changes in the receptor interactome are propagated throughout the network to affect downstream protein interactions and thereby dynamically shape the network topology used to transduce a signal. This theory was recently confirmed by analysis of the dynamic ERK interactome in the control of differentiation versus proliferation in PC12 cells 31 . The ERK pathway consists of a three-tiered kinase cascade, Raf-MEK-ERK and is a main effector of EGFR signalling (FIG. 1) which mediates many responses to EGF that are subverted in cancer, such as cell proliferation, transformation, differentiation, migration and survival. Stable isotope labelling with amino acids in cell culture (SILAC)-based quantitative proteomics was used to determine changes in the ERK interactome in response to nerve growth factor (NGF; which induces differentiation) and EGF (which induces proliferation). The results of this study increased the number of proteins identified in the ERK interactome from 170 proteins 32 to >280. Importantly, 60 protein interactions changed in a differentiation-dependent manner. Detailed analysis of a subset of ERK interactors showed that these interactors regulate the pathway at different steps, including the activation kinetics of ERK, crosstalk with other pathways and phosphorylation of transcription factors. These biochemical data were incorporated into a mathematical 
Two-dimensional polyacrylamide gel electrophoresis (PaGe)
The sensitivity, linear dynamic range and robustness of this method have been greatly improved by the use of fluorescent stains and tags
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, and the analysis has been substantially simplified by several automated software packages. Proteins are identified by MS.
Isotopic labelling
The ability of MS to resolve heavy and light isotopically labelled molecules has been extensively used to design approaches for quantitation [112] [113] [114] [115] . The common labelling methods are metabolic, typified by stable isotope labelling with amino acids in cell culture (SILAC) [116] [117] [118] . Samples are grown on media containing a normal or isotopically labelled form of an amino acid or food source 119 . Comparison of protein abundance uses the light and heavy peaks observed in the mass spectrum. SILAC is best suited for cultured cells but has also been used to label whole animals 120 . Chemically reactive, isotopically labelled reagents are used to tag the protein or peptides (such as isotope-coded affinity tag (ICAT) 121 and isobaric tag for relative and absolute quantitation (iTRAQ)
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). For absolute quantification (AQUA), isotopically labelled peptides are added to the sample as an internal standard for quantification 123 .
Label-free
Improvements in the robustness and reproducibility of both MS and chromatography paved the way for direct comparisons between MS data sets using retention time, mass and ion intensity 124, 125 . As they are uncomplicated and reasonably reliable, label-free approaches may become the methods of choice for proteomics experiments.
antibody arrays
The repertoire of antibodies that have highly selective binding to native or posttranslationally modified protein epitopes has expanded rapidly and the arrays based on these antibodies have been used extensively to quantify antigens 126, 127 . This approach has now developed into a thriving business and many companies offer commercial and bespoke custom arrays.
In situ fluorescence
The use of a fusion protein approach, in which the protein of interest is genetically fused to green fluorescent protein (GFP) or the range of GFP analogues that have now been developed, can allow determination of the cellular localization and abundance of a protein using fluorescence microscopy 128 . Automated methods for tracking cells and determining abundance and localization are only just becoming available. model, which revealed that the EGF and NGF pathways are under a distributed control mechanism rather than governed by a single master switch.
These results show that signalling pathways rely on protein interactions, which distribute control throughout the network, and that quantitative interaction proteomics is a formidable tool to map these pathways and their topologies. Furthermore, these findings predict that it is difficult to disrupt signalling networks by interventions targeting a single node, adding a mechanistic explanation to the clinical experience that the efficacy of single-agent cancer therapies is usually limited. These studies are complemented by the analysis of downstream phosphorylation events that we discuss further below.
The proteomic studies of the EGFR pathway demonstrate how signalling specificity is achieved through regulated protein interactions and how receptor overexpression can expand the number of interaction partners sufficiently to drive oncogenesis. This theme of oncogenesis, which results from the unwanted spread of signalling into many pathways owing to an expansion of the number of protein complexes assembled, is more clearly demonstrated when signal regulation is usurped by an oncoprotein. BCR-ABL1 is an oncogenic fusion protein that results from the chromosomal translocation that causes CML and inhibition of its kinase activity can reverse disease 33, 34 . The translocation that results in BCR-ABL1 is a rare case in which human tumorigenesis can be tied to a single genetic event based on molecular evidence and the unprecedented clinical success of the BCR-ABL1 inhibitor imatinib (Gleevec; Novartis) 5 . What causes this exception? Classical biochemical studies suggested that BCR-ABL1 is a constitutively active tyrosine kinase and 'super adaptor' that interacted with almost every pathway implicated in the oncogenic transformation of haematopoietic cells and fibroblasts 35 (FIG. 2) . The challenge was to define which of these pathways is required for BCR-ABL1-induced transformation. An interaction proteome screen of BCR-ABL1-associated proteins revealed a network of several hundred proteins that act as direct or indirect interactors 36 . Evaluation of the highly connected hubs revealed only seven core components: GRB2, Src homology 2 domain-containing transforming protein 1 (SHC1), CRKL, CBL, p85 (also known as PIK3R2), suppressor of T cell receptor signalling 1 (STS1, also known as uBASH3B) and SH2 domain-containing inositol phosphatase 2 (SHIP2, also known as INPPL1), which coordinate a signalling network comprising several hundred proteins (FIG. 2) . Interestingly, many of the core components of this network are scaffolds, suggesting that BCR-ABL1 signalling is orchestrated through propagating layers of protein complexes. BCR-ABL1 kinase inhibitors disrupted this network, leading the authors to conclude that the action of these drugs should be considered to interfere with the equilibrium state of an intricate network of protein complexes rather than just inhibit a single component. Given that several proteins interact with more than one of the seven core components, even the perturbation of a single interaction should have repercussions throughout the network, as it could shift the equilibrium composition of other complexes. This view may become important in the quest for alternative strategies that can circumvent resistance to tyrosine kinase inhibitors.
The big question is whether these findings from cultured cells translate to the clinic? This question was addressed mainly by using reverse-phase protein microarrays, on which lysates of tumour samples are arrayed and interrogated with antibodies. This strategy only allows targeted studies but can examine large numbers of patients and functions using the limited amounts On activation (by ligand binding), the epidermal growth factor receptor (EGFR, also known as ERBB1) autophosphorylates tyrosine residues in its cytoplasmic domain, which serve as docking sites for the assembly of protein complexes that transduce EGF signals to generate specific biological responses. It is unlikely that the full complement of binding partners is recruited to each receptor and more plausible that individual EGFRs form complexes that have different compositions. In addition, all four members of the ErbB family (EGFR, ERBB2 (also known as HER2), ERBB3 and ERBB4) can form heterodimers (not shown), which share common binding proteins but, owing to the different representation of docking sites, assemble receptor complexes with different signalling properties 27 . The EGFR network has been reviewed in detail elsewhere 145, 146 and only the better characterized downstream pathways are shown here. Kinases are light blue, scaffolds are dark blue, adaptor proteins are yellow, G proteins are green and transcription factors are orange. Phospholipase Cγ (PLCγ) is a phospholipase, CBL is an ubiquitin ligase, son of sevenless homologue (SOS) is a guanine nucleotide exchange factor. Small molecule second messengers are red: phosphatidylinositol-4,5-bisphosphate (PIP2), diacylglycerol (DAG), inositol-1,4,5-triphosphate (IP3) and Ca
2+
. The downstream pathway discussed in this Review is the ERK pathway, which is initiated through the recruitment of a protein complex that contains the Src homology 2 domain-containing (SHC) and growth factor receptor-bound protein 2 (GRB2) adaptor proteins and the exchange factor SOS to activated EGFR. SOS exchanges GDP for GTP on Ras, which induces a conformational change that enables Ras to bind Raf kinases with high affinity. Raf activation is a complex process, involving dephosphorylation, phosphorylation, homo-and heterodimerization and binding to the kinase suppressor of ras 1 (KSR1) scaffold [147] [148] [149] . Activated Raf phosphorylates and activates MEK, which in turn phosphorylates and activates ERK. ERK exerts its different biological effects through many substrates 32 , including transcription factors. AP1, activator protein 1; CAMK, calcium/calmodulin-dependent protein kinase; CREB, cyclic AMP-responsive element-binding protein; EGR1, early growth response 1; FAK, focal adhesion kinase; MEF2, myocyte enhancer factor 2; PKC, protein kinase C; STAT, signal transducer and activator of transcription. Although the role of scaffolds in cancer still needs to be determined, we briefly discuss them as they play fundamental parts in regulating both the steady-state and acuteresponse kinetics of many pathways involved in cancer. Scaffolds seem to be most relevant to mechanisms of nononcogene addiction 22 , whereby normal components of signalling networks support the aberrant components. Aberrations in ERK signalling are common in cancer 38 and hence we discuss two ERK pathway scaffolds.
The kinase suppressor of ras (KSR) proteins scaffold the three-tiered Raf-MEK-ERK module and contribute to the regulation of its signalling dynamics and spatiotemporal control. KSR1 is not essential for, but enhances ERK activation 39 . Importantly, knocking out Ksr1 restrains transformation by oncogenic HRAS-G12V in cultured cells 40 and HRAS-G12V-driven skin carcinogenesis in mice 41 . KSR1 constitutively interacts with MEK and the KSR1-MEK complex translocates to the plasma membrane on mitogen stimulation 42 . MEK bound to KSR1 also promotes the recruitment of BRAF, which enhances MEK phosphorylation by BRAF. Interestingly, ERK binding induces feedback phosphorylation of KSR1 and BRAF by ERK, which promotes the dissociation of BRAF and KSR1 and their release from the plasma membrane into the cytosol. It is unclear whether this is a purely negative feedback pathway that limits ERK activation, or whether this feedback also has a role in ensuring the turnover of client proteins on the scaffold and in signal localization. KSR1 also directly allosterically activates Raf kinases by forming side-to-side dimers 43 . KSR1 selectively interacts with ERK dimers and confines ERK signalling to cytosolic substrates, and the expression of ERK point mutants that prevent ERK dimerization counteracts cellular transformation in vitro and tumour development in mouse xenograft models 44 . Thus, KSR1 can control several aspects of ERK signalling, including substrate specificity and spatio-temporal activation kinetics.
Recently, the KSR2 interactome was studied using quantitative MS-based proteomics to compare proteins that bind to KSR2 in the presence and absence of tumour necrosis factor-α (TNFα) stimulation 45 . Of >100 proteins potentially in the complex, approximately 40 were recruited on TNFα stimulation, highlighting the highly dynamic properties of this signalling complex. Interestingly, KSR2 recruited ARAF rather than RAF1 or BRAF. ARAF is a poor activator of MEK and its main, kinase-independent, function is as an inhibitor of the pro-apoptotic mammalian STE20-like protein kinase 2 (MST2, also known as STK3) pathway 46 , indicating that KSR2 may have a role in redirecting ARAF to the ERK pathway. As scaffolding vastly accelerates reaction rates by co-localizing enzymes and substrates 47 , KSR2-bound ARAF is expected to be an effective MEK activator. Thus, this shift of ARAF from its anti-apoptotic function in the MST2 pathway to the mitogenic ERK pathway may contribute to oncogenic transformation.
A detailed comparison of the KSR1 and KSR2 interactomes showed the similarity of these scaffolds in promoting RTK-mediated ERK signalling but also identified specific interactions. For example, the calciumdependent phosphatase calcineurin only binds to KSR2 (REF. 48 ). In response to calcium signals, calcineurin dephosphorylates the 14-3-3 binding sites on KSR2, which allows KSR2 to be recruited to the plasma membrane and activation of the ERK pathway 48 . Another proteomic study showed that KSR2 binds to AMP kinase (AMPK, also known as PRKAB1), mediating its stimulatory effects on glucose uptake and fatty acid oxidation 49 . This observation raises an interesting hypothesis: that KSR2 may coordinate links between mitogenic signalling and metabolic pathways by binding and coordinating the functions of ARAF and AMPK. ARAF can bind and inhibit . They comprise adaptor proteins (blue), phosphatases (orange) and the regulatory p85 subunit of PI3K (green). Selected downstream signalling pathways are depicted in light green and biological outcomes in yellow. Most biological effects are regulated through multiple pathways; for example, actin polymerization is regulated through the growth factor receptor-bound protein 2 (GRB2)-related adaptor protein 2 (GRAP2, also known as GADS)-lymphocyte cytosolic protein 2 (LCP2, also known as SLP76)-Nck adaptor pathway 150 or through SH2 domain-containing inositol phosphatase 2 (SHIP2) regulation of phosphatidylinositol-3,4,5-trisphosphate levels 151 . The scheme is highly simplified for clarity. Arrows do not imply direct connections and may summarize several steps. The figure is based on data from Brehme et al.
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. AP2, adaptor protein complex 2; CSK, c-src tyrosine kinase; SHC1, Src homology 2 domain-containing 1; STS1, suppressor of T cell receptor signalling 1.
Warburg effect
This was named after a discovery made by the German biochemist Otto Warburg in the 1920s that cancer cells predominantly use anaerobic glycolysis rather than oxidative phosphorylation, even when oxygen is abundant. As a result, pyruvate is converted to lactate instead of being oxidized by the mitochondria of cancer cells.
O-linked N-acetylglucosamine acylation (O-GlcNAcylation)
A form of glycosylation found in nuclear and cytosolic proteins in which O-GlcNAc is added to the hydroxyl groups of serine and threonine residues that can also serve as phosphorylation sites.
Isobaric tag for relative and absolute quantitation (iTRAQ)
A stable isotope labelling method for the quantitation of peptides by MS, in which a molecule containing normal or heavy isotopes is used to chemically modify the proteins or peptides from each individual sample. The fragmentation of the labelled molecules then gives rise to specific reporter ions that can be used to measure the relative amounts of each protein present in each sample.
pyruvate kinase M2 (PKM2) 50 . In many cancers, PKM2 is aberrantly expressed in its low-activity dimeric form, which favours aerobic glycolysis -the hallmark of the Warburg effect 51 . Thus, KSR2 could enhance AMPKmediated glucose uptake and PKM2 inhibition by ARAF, thereby promoting the Warburg effect and tumour growth. Consequently, KSR2 downregulation should ameliorate the Warburg effect and slow tumour growth, a prediction that is easily testable as Ksr2 -/-mice are available 49 . The above examples illustrate the key role of protein complexes in signalling and equally highlight the importance of dynamic changes in the interactions that ensure the proper interpretation of signals and responses to signals. Conceptually, this view has important implications. They include the notion that connections in signalling pathways are not hardwired, that a protein with a defined biochemical function can adopt different biological functionalities as part of different protein complexes and that the kinetics of signalling specificity intimately involve dynamic changes in protein interactions. How are connections in signalling pathways brought about? undoubtedly, PTMs are a salient part of the answer. The specific roles of PTMs in determining protein complex formation are just emerging but many proteomic techniques for PTM analysis are available. In the following section, we briefly review how these technologies have been applied to study dynamic processes in cell signalling.
Post-translational modifications
PTMs are widely studied dynamic processes in cell signalling, which is not surprising considering the fundamental roles they have in regulating signalling pathways, and many studies have mapped cancer-associated PTMs. Phosphorylation of serine, threonine and tyrosine residues have received the most attention from the proteomics community, although ubiquitylation, acylation and glycosylation are coming into the limelight. O-linked N-acetylglucosamine acylation (O-GlcNAcylation) is also receiving considerable interest, mainly owing to its competing role in regulating phosphorylation by blocking potential phosphorylation sites.
Phosphorylation. Quantitative methods for the study of protein phosphorylation have been described elsewhere 13, [52] [53] [54] [55] [56] . The first phosphoproteome to be extensively studied was that of EGFR activation (reviewed by Blagoev 24 ) and several other RTK pathways have now been described. Global tyrosine phosphorylation is usually mapped using enrichment with anti-phosphotyrosine antibodies and subsequent MS analysis. using this method, time-course studies of EGF-induced tyrosine phosphorylation and comparisons of signalling between different RTKs were performed 57 . For example, SILACbased quantitative proteomics was used to compare the tyrosine phosphorylation induced by EGF versus that induced by platelet-derived growth factor (PDGF) in human mesenchymal stem cells 58 . EGF induces osteogenic differentiation whereas PDGF sustains proliferation and migration 59 . Most tyrosine phosphorylation events were common to both growth factors, except the PI3K pathway, which was exclusively stimulated by PDGF.
Inhibiting PI3K converted PDGF to a differentiation factor, elegantly demonstrating that biological specificity of RTK signalling is encoded by distinct biochemical differences in downstream signalling pathways that arise from the protein complexes assembled at RTKs. A more recent study that analysed the tyrosine phosphorylation induced by EGF in human mammary epithelial cells revealed significantly different stoichiometries of phosphorylation at different sites in the same protein 60 , suggesting intricate temporal and dynamic regulation of phosphorylation.
Quantitative proteomics was also successfully used to map the tyrosine phosphorylation network induced by cancer-associated EGFR mutants. Glioblastoma (or astrocytoma grade IV) is a highly malignant brain tumour and often expresses a truncated EGFR mutant, EGFRvIII, which is expressed from an amplified gene locus and enhances malignant behaviour in a dose-dependent manner 61 . Isobaric tag for relative and absolute quantitation (iTRAQ) analysis of glioblastoma cell lines that expressed different levels of EGFRvIII or a kinase-dead EGFRvIII as a control revealed that increasing EGFRvIII expression shifts signalling from ERK and STAT3 towards the PI3K pathway and also induces phosphorylation and transactivation of the hepatocyte growth factor receptor MET 62 . Consequently, the combination of EGF and MET inhibitors synergized to kill glioblastoma cells in vitro, producing a rational drug combination based on phosphoproteomics data.
Another SILAC-based proteomics study in non-small-cell lung cancer (NSCLC) cell lines compared phosphotyrosine signalling induced by wild-type EGFR, mutationactivated EGFR and overexpressed MET 63 . It revealed networks that extensively overlapped in the regulation of cell adhesion, motility, proliferation and survival. Interestingly, mutant EGFRs preferentially induced phosphorylation of cytoskeletal proteins, scaffolds implicated in cytoskeletal regulation and motility, and negative feedback inhibitors of EGFR signalling, such as sprouty 1 (SPRY1), SPRY2, SPRY4 and mitogen-inducible gene 6 (MIG6, also known as ERRFI1). The functional effects of these phosphorylation events are largely unknown but it is tempting to speculate that mutant EGFRs can sabotage the function of physiological feedback inhibitors. This hypothesis is consistent with observations that EGFR feedback inhibitors are often downregulated in cancers 64 . Crosstalk between MET and mutant EGFRs provided mutual activation of the respective receptors and downstream signalling pathways 63 . Interestingly, the sensitivity to EGFR and MET inhibitors as measured by biochemical outputs correlated with the extent of control of the respective receptors over the downstream network. This puts an interesting twist on the observation discussed above that EGFR oncogenicity increases with the number of pathways it engages [28] [29] [30] , as such functional expansion should also increase the vulnerability of the downstream network to receptor inhibition. The available clinical experience with EGFR inhibitors shows that spectacular regressions are achievable in patients with NSCLC but this only occurs in a small subset of patients and does not have lasting effects 65 . Does this reflect an arms race between the increasing fragility and adaptive potential of RTK networks, which is afforded by the recruitment of an increasing number
Immobilized metal ion affinity chromatography (IMAC)
A method for the enrichment of phosphopeptides that exploits the propensity of metal ions such as iron and gallium to bind phosphate groups.
of downstream effectors? This hypothesis suggests a counterintuitive approach of combining EGFR inhibitors with inhibitors of downstream pathways to boost drug efficacy and prevent resistance. The combined inhibition of a receptor and a downstream effector could offer simple, general and hence attractive guidelines for the design of combination therapies and it seems worthwhile to explore this possibility further.
A large-scale phosphotyrosine proteomic screen using 41 NSCLC cell lines and >150 NSCLC tumours found many RTKs, including EGFR and MET, and non-RTKs were activated in NSCLC 66 . The contribution of most of these kinases to NSCLC pathogenesis is unknown but an important prediction of this study is that the drug responsiveness of individual tumours should be highly dependent on whether these activated kinases function as part of hierarchical networks or in independent pathways. If they form hierarchical networks, inhibition of the master kinase will be therapeutically effective, as demonstrated by the spectacular efficacies of BCR-ABL1 inhibitors in CML. If these kinases function in independent networks or as part of redundant topologies, combination therapy seems necessary. Therefore, for personalized therapy, it will be important to map kinase activation profiles to network connectivity maps that control specific biological responses. This idea has also been adopted by the pharmaceutical industry, especially for kinase inhibitor screening
.
The idea of correlating phosphotryosine networks with specific biological behaviours was also borne out in studies on the effects of human ERBB2 in human mammary epithelial cells (HMECs) 67, 68 . ERBB2 is overexpressed in ~25% of breast cancers and strongly correlates with poor prognosis. Although ERBB2 lacks a known ligand, it can heterodimerize with EGFR and alter EGFR signalling. Quantitative MS based on iTRAQ labelling was used to map phosphotyrosine networks in parental HMECs and HMECs engineered to over express ERBB2 that were stimulated with EGF or heregulin (also known as neuregulin 1) 67 . The results show that in ERBB2-overexpressing cells, EGF stimulates migration through multiple signalling pathways, whereas heregulin uses a subset of the migration network. The application of regression-based computational modelling identified combinations of phosphorylation sites that correlate with proliferation and migration. Subsequent refinement of the model 68 allowed the identification of phosphotyrosine network elements that differentially control migration and proliferation. This culminated in the description of nine phosphorylation sites on six proteins that were associated with the PI3K pathway and endocytosis. These sites served as a 'network gauge' that captured the predictive capability of the full model. This result also elegantly demonstrates the analytical power added by computational modelling to the interpretation of complex dynamic data sets.
Phosphoserine and phosphothreonine antibodies are less well developed than phosphotyrosine antibodies, and most global phosphoproteome studies use chromatographic enrichment technologies. These usually exploit the propensity of TiO 2 or Fe 3+ to interact with phosphate groups and are often combined with a preceding separation step that counterselects phosphopeptides such as strong cation exchange columns 69 . Chromatographic enrichment approaches are available in several variations, which enrich overlapping but distinct fractions of the phosphoproteome 70 . It is now possible to identify 10,000-20,000 phosphorylation sites. For example, proteomic analysis of phosphorylation induced by the fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutant tyrosine kinase quantified >12,000 phosphorylation sites and demonstrated subcellular localization-specific signalling of FLT3 (REF. 71 ). FLT3-ITD consists of in-frame tandem duplications of the juxtamembrane domain of FLT3 and is the most frequent oncogenic FLT3 mutation in acute myeloid leukaemia (AML), causing constitutive activation of FLT3 and retardation of trafficking through the endoplasmic reticulum (ER). When localized at the ER, FLT3-ITD aberrantly activates STAT5 signalling and fails to activate the PI3K and ERK pathways that are targets of ligandactivated wild-type FLT3. By contrast, when located at the membrane, FLT3-ITD preferentially activates PI3K and ERK over STAT5. These pathway-specific effects were reflected in the global phosphoproteome and also helped identify putative downstream targets of AKT and proviral integration site (PIM) kinases.
An interesting approach to functional studies is to combine global phosphoproteomics with small interfering RNA (siRNA) knockdown studies. An example is the quantitative proteomic assessment of early signalling events in integrin signalling 72 . Integrin-mediated cell adhesion and anti-apoptotic signalling is essential for cancer cell spread and invasion. SILAC combined with immobilized metal ion affinity chromatography (IMAC)
Box 2 | Kinase profiling and kinomics
Kinase profiling refers to the process of screening kinase inhibitors for activity and selectivity
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. Given the part that aberrant kinase activity plays in cancer and the huge efforts to study kinases, their substrates and inhibitors, the increase in the number of kinase inhibitors being translated into anticancer drugs in recent years is not surprising (it is estimated that around one-third of all major clinical trials currently involve kinase inhibitors). However, the first kinase inhibitor (imatinib) only received clinical approval in 2001. Analysis of the human genome initially predicted the existence of 518 kinases 130 , most of which have now been validated and >400 of these are currently available in various screens. However, this is unlikely to be the full story, as new kinases are being identified and tissue-specific roles of kinases are being elucidated 131 . Methods to identify kinases generally rely on the use of peptide substrates in microtitre plate, bead or array format that can be used to measure the activity of a set of purified kinases, although with recent improvements [132] [133] [134] [135] , methods are getting closer to native in vivo conditions. Miniaturization through microfluidics and new detection methods are greatly improving sensitivity and reducing costs. The benefits of these approaches are obvious: they are highly parallel, so many compounds and kinases can be tested, and quantitative analysis allows the crucial question of off-target activity to be addressed. Kinomics 130 is formally the identification of kinases at the genetic, or preferably proteomic, level. However, this term should be expanded to include the challenging task of identifying kinase targets and elucidating the cellular pathways and networks in which they are involved and the complex regulation of these kinases. Proteomics approaches coupled to modelling through systems biology methods are in the forefront of the techniques being applied. A substantial remaining challenge is the identification of the downstream effector kinases that are the best drug targets. Furthermore, chemical proteomics is a valuable tool to identify on-and off-target interactions of individual kinase inhibitors 
Electron transfer dissociation (ETD)
A recently introduced MS method for the fragmentation of molecules by transferring electrons from anion radicals to positively charged ions. It is a non-ergodic (rapid, kinetically controlled) process, so energy is not redistributed and many bonds are broken in the molecule, not just the weakest ones as seen in collision-induced dissociation.
WD40 domain
A protein domain consisting of 4-16 repeats of an approximately 40 amino acid-long motif that ends with a W-D (tryptophan-aspartic acid) dipeptide. The WD40 domains form a circular β-sheet propeller structure that serves as a structural platform for protein interactions and the specificity of the interactions is determined by sequences outside the WD repeats.
enrichment showed that >500 phosphorylation sites in 357 proteins changed when integrins interacted with collagen, a common integrin ligand in the extracellular matrix. siRNA screens against 33 of these proteins with kinase or phosphatase activity identified three integrinregulated kinases, p21-activated kinase 2 (PAK2), G protein-coupled receptor kinase 6 (GRK6) and DBF4, which are important in cell migration. Recent evidence suggests that these proteins are deregulated in cancer. PAK2 is hyperphosphorylated in ovarian cancer 73 , and a siRNA screen identified that GRK6 was required for the viability of myeloma cells but not normal cells 74 . DBF4 is a regulatory subunit of the cell cycle kinase CDC7 and this complex is overexpressed in various cancer cell lines and human cancers 75 .
The focus on phosphoproteomics in recent years and the application of functional proteomics methods 76 led to the identification of O-GlcNAcylation as an important PTM in signalling. As O-GlcNAcylation occurs at serine and threonine residues that are also targets for phosphorylation, they mutually exclude each other, resulting in dynamic crosstalk between phosphorylation and O-GlcNAcylation 77 . Although many of the (patho)physiological consequences of this crosstalk remain to be explored, it has been implicated in several diseases, including cancer 78 , and demonstrated to be crucial for cellular processes that are important in cancer biology such as cytokinesis 79 . The application of improved MS techniques (such as electron transfer dissociation (ETD)) for detecting O-GlcNAcylation 80 or the parallel detection of phosphorylation and glycosylation 81 will likely increase attention to this field.
Ubiquitylation. ubiquitylation and the proteasomal pathway have key functions in oncogenesis and cancer [82] [83] [84] [85] [86] [87] [88] ( FIG. 3) , typified by the tumour suppressor p53 (REFS 89, 90) , and are being investigated as pharmaceutical targets [91] [92] [93] [94] . Since the early use of functional proteomics to identify the structure and substrate specificity for the S phase kinaseassociated protein 1 (SKP1)-cullin 1 (CuL1)-F-box (SCF) complex 95, 96 , this method has continued to have an important role in the study of ubiquitylation, and in identifying the components of ligase complexes and those involved in the ubiquitylation of proteins 97 . Recent studies have also focused on the non-classical ligases such as the damage-specific DNA-binding protein 1 (DDB1)-CuL4A-regulator of cullins 1 (ROC1, also known as RBX1) E3 ubiquitin ligase, a complex that lacks a SKP1-like adaptor and is involved in the regulation of DNA repair 98 . TAP affinity purification of the complex and subsequent MS analysis were used to identify a novel family of 16 WD40 domain-containing proteins that recruit the substrate to the complex 99 . This novel family of proteins was called the DDB1-CuL4A-associated WD40 domain proteins (DCAF proteins) and includes DDB2, a protein mutated in the cancer-predisposing syndrome xeroderma pigmentosum. However, given the connection of this complex with DNA repair, it seems likely that it has a much broader role in cancer and in sensitivity of cells to DNA-damaging treatments. Methods are continually being improved for the global identification of ubiquitylation sites 100 and to identify substrates in specific pathways 101 . In addition to MS approaches, protein arrays are valuable tools for identifying substrates for PTMs. As these assays are done in vitro, versatile manipulations and comparisons are possible. Protein microarrays displaying >8,000 human proteins were exposed to cell extracts that replicate the mitosis checkpoint and anaphase release to identify targets of the anaphase-promoting complex (APC) 102 . The APC is a multiprotein complex with E3 ubiquitin ligase activity that promotes cell cycle progression during mitosis. Its substrates include mitotic cyclins and many other proteins that orchestrate this cell cycle transition. The array-based ubiquitylation assay compared extracts that contained inhibited and activated APC, detecting most of the known substrates and seven potential new substrates. A similar experiment was used to identify and compare substrates for NEDD4 and NEDD4L 103 . In addition to the shared substrates identified, NEDD4 showed a preference for tyrosine kinases, and NEDD4 knockdown sustained tyrosine kinase signalling. NEDD4 family members regulate various pathways and cellular functions that are implicated in cancer, such as many RTK pathways and transcription factors, and are found overexpressed in breast, prostate and pancreatic cancers 104 . This brief description of PTM aberrations in cancer is far from complete and there are many other PTMs that are altered in cancer
. However, PTMs are Figure 3 | The ubiquitin system. Ubiquitin (Ub) is a small protein that is transferred as a versatile regulatory post-translational modification (PTM) to target proteins in a three-step process 152 . In the first step, an E1 ubiquitin-activating enzyme uses ATP to form a covalent thioester with ubiquitin. E1 then transfers the ubiquitin moiety onto an ubiquitin-conjugating enzyme E2. E2 associates with one of several hundred E3 ubiquitin ligases which provide specificity by also binding the target protein. The E2-binding and target recognition domains can reside in one protein (as shown) or in different proteins that are part of a ligase complex. Finally, the ubiquitin moiety is transferred to a lysine residue in the target protein directly or through an E3 ubiquitin ligase. Further ubiquitins can be added to lysines in ubiquitin itself. Depending on the number of ubiquitin moieties transferred and the linkage type, ubiquitylation can have different functions that are often derailed in cancer 83 and many other diseases 153 .
Cyclin
A regulatory subunit that is essential for the activity of cell cycle-dependent kinases (CDKs). Its name derives from the periodic expression of cyclins during the cell cycle, which is due to the regulated degradation by the ubiquitinproteasome system that is thought to drive the cell cycle.
emerging as important drug targets. The high hopes and resources invested in kinase inhibitor drugs are inextricably linked to their ability to prevent regulatory phosphorylations of crucial substrates. We soon may witness similar prolific efforts to target other PTMs for cancer therapy such as ubiquitylation 92 . Notably, the validation of PTM targets is enabled by proteomics. PTMs are largely undetectable in genomic studies and to fully exploit their therapeutic potential, it will be necessary to understand the dynamics of PTM turnover. It is tempting to speculate that PTM dynamics also contribute to the well-known heterogeneity in cancer. Dynamic changes in protein expression and localization can determine the drug sensitivity of cancer cells 105 , and dynamic changes in PTMs could vastly expand the window of opportunities of cancer cells to escape adverse conditions and therapy.
Towards single-cell proteomics New techniques enabling the functional analysis of individual cells are increasingly being used to address the heterogeneity of cancer cells, especially in terms of drug resistance. One of the first methods was PhosphoFlow, invented by the Nolan group 98 . This technique uses phospho-specific antibodies to label antigens in fixed cells. Subsequent analysis by flow cytometry provides data at the single-cell and population levels that allow the investigation of heterogeneity and are applicable to the modelling of cancer signalling pathways 106 . More recently, Cohen et al. tagged ~1,000 individual endogenous proteins in lung cancer cells with a fluorophore and monitored their expression and subcellular location by automated time-lapse imaging 105 . Treatment with the topoisomerase 1 inhibitor camptothecin caused the rapid relocation of proteins that are associated with the mechanism of drug action and slower changes in protein abundance. Interestingly, although most drug-induced responses were similar in individual cells across the population, a subset of 24 proteins showed high cell-to-cell variability 1 day after drug exposure. The upregulation of two of these proteins, the RNA helicase DEAD box polypeptide 5 (DDX5) and replication factor C1 (RFC1), correlated with drug resistance and cell survival, showing that escape mechanisms can result from changes in protein dynamics that are unique to a subset of a cell population. This is an intriguing proposition for the development of drug resistance that warrants further investigation in preclinical cancer models.
A different approach used a microfluidic platform that traps ~1,000 individual cells and analyses their behaviour using imaging, optical indicator dyes and fluorescent antibodies 4 . This platform was used to assess the signalling dynamics of normal human haematopoietic stem cells (HSCs) and CML stem cells (CML-SCs) in response to the second-generation BCR-ABL1 inhibitor dasatinib (Sprycel; BristolMyers Squibb). Although significant differences in the responses of individual cells were observed, at the population level dasatinib was more cytotoxic to HSCs than CML-SCs, and strongly and selectively inhibited migration of CML-SCs. Thus, single-cell analysis can reveal important information on divergent and synchronized behaviour within cell populations, especially in regard to drug action. It would be fascinating to combine these approaches to collect more detailed information on cancer cell heterogeneity.
Perspective
Although this Review discusses only a small fraction of studies, it illustrates the power of functional proteomics in mapping cancer signalling pathways. The biggest
Box 3 | Other post-translational modifications
Protein function is crucially regulated by post-translational modifications (PTMs) and the role of PTM aberrations in the faulty regulation of cancer signalling networks is becoming increasingly appreciated. Proteomics is currently expanding its scope beyond phosphorylation, delivering exciting results on other PTMs, which are described below.
acetylation and methylation
The regulation of gene expression by the acetylation and methylation of lysines and arginines in histones is well established, and the term the 'histone code' highlights the importance of this epigenetic control 137 . Silencing of tumour suppressor gene expression owing to subversion of the histone code is well known 137 . However, proteomics has enabled a systematic study of these histone modifications 138 . Importantly, proteomics identified many other chromatin-independent targets. For example, stable isotope labelling with amino acids in cell culture (SILAC) analysis of breast cancer cells treated with vorinostat (Zolinza; Merck), a histone deacetylase (HDAC) inhibitor, revealed changes in the expression of transcription factors and metabolic, structural, chaperone and cell cycle proteins 139 . HDAC6 was identified as an inhibitor of EGFR endocytosis by deacetylating microtubules 140 . acylation A well-characterized example of acylation that is relevant to cancer is the modification of Ras proteins by farnesylation, geranylation and palmitoylation, which localizes Ras to distinct membrane compartments 141 . As Ras mutations are frequent in human cancers, the Ras-modifying acylases became major drug targets, unfortunately with disappointing clinical results
142
. Much effort was invested to understand the opportunities and failures of clinically targeting Ras acylases, but quantitative proteomic techniques were only recently developed to identify palmitoylated proteins 143. Oxidative modifications and cysteine nitrosylation These modifications have also been shown to play an important part in signalling 144 . They are likely to have a role in cancer owing to the hypoxic and inflammatory environment associated with cancer, but systematic proteomics studies are lagging behind.
Micro-engineering
The use of micro-fabricated devices that have small (micron)-scale features (such as channels, wells and vessels) to allow the processing of small volumes of fluid.
challenge is to bring proteomics technologies to clinical applications. Despite impressive progress, especially in biomarker discovery, substantial hurdles remain. Most current proteomics technologies are too slow, too complex and too expensive to be used in the clinical laboratory, and the existence of many different experimental approaches leaves a deficit in standardization. However, further innovations that may overcome these barriers are on the horizon. Although MS is dominating the field, alternative technologies are appearing. Great progress is to be expected from array-based methods, optical methods and micro-engineering approaches. Although these methods cannot identify proteins de novo, their attractiveness lies in their multiplexing capabilities, throughput and prospect of reducing analytical costs. In particular, methods based on flow cytometry, protein and tissue microarrays and micro-engineered devices are amenable to adaptation to the clinical laboratory.
Our capability to routinely identify or test thousands of proteins per analysis has shifted the bottleneck in proteomics towards data analysis and interpretation.
The increasing use of advanced bioinformatics and systems biology tools is beginning to unlock network properties 107 . Recent examples are the development of a predictor for breast cancer prognosis based on the modularity of protein interaction networks 108 and the identification of cancer-associated phosphorylation networks through the combined alignment of conserved phosphorylation sites and kinase-substrate networks 109 . This latter study also showed that we still miss large parts of phosphorylation networks.
As we only begin to apply proteomics to unravel the role of other PTMs, such as ubiquitylation, sumoylation and glycosylation, in signalling we can expect a further stream of data. It will be a challenging and informative task to understand the regulatory interplay between the different PTMs both at the level of individual proteins and in networks. In addition, these investigations may provide molecular alterations that can serve as biomarkers for cancer and thereby bridge the current gap between mechanistic understanding and mainly phenomenological markers.
